Synta Pharmaceuticals Corporation http://www.alacrastore.com/company-snapshot/Synta_Pharmaceuticals_Corporation-2529072 Monday, October 13, 2008 1:54:23 AM 2529072 Synta Pharmaceuticals Corporation en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/ccbn/T1912005ccbn/T1912005norm...Good day and welcome to the Synta Pharmaceuticals Second Quarter #### Financial Results Conference call. Today's conference call is being recorded and webcast. At this time, for opening remarks, I would like to turn the call over to Rob Kloppenburg, Vice President of Investor Relations and Corporate Communications at Synta Pharmaceuticals. Please go ahead, sir. ... 8/7/2008 4:05:00 PMSynta Pharmaceuticals Corp.54.0000FinalSynta Pharmaceuticals Corp. Q2 2008 Earnings Conference Call TranscriptSNTA10:00am ETTranscriptT1912005Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/BW-0001-26998768newstex/BW-0001-26998768xml Jul. ##, #### (Business Wire) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced...0700000007005000040000000400200004002006040160000401604804016018070030000700300107014000070140121300000013010000130100057/29/2008 9:21:44 AM180000001800800018004000Business WireBW-0001-26998768SYNTA PHARMACEUTICALS CORP.SNTANewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1848424ccbn/T1848424norm...Good day and welcome to the Synta Pharmaceuticals first quarter #### financial results conference call. Today's conference call is being recorded and webcast. At this time for opening remarks, I would like to turn the call over to Rob Kloppenburg, Vice President of Investor Relations and Corporation Communications at Synta Pharmaceuticals. Please go ahead, sir. ... 5/14/2008 11:06:00 AMSynta Pharmaceuticals Corp.54.0000FinalQ1 2008 Synta Pharmaceuticals Corp. Earnings Conference Call TranscriptSNTA10:00am ETTranscriptT1848424Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1790736ccbn/T1790736norm...Today's conference call is being recorded and webcast. At this time for opening remarks, I would like to turn the conference over to Rob Kloppenburg, Vice President of Investor Relations and Corporate Communications at Synta Pharmaceuticals. Please go ahead, sir. ... 3/20/2008 11:07:00 AMSynta Pharmaceuticals Corp.54.0000FinalQ4 2007 Synta Pharmaceuticals Corp. Earnings Conference Call TranscriptSNTA10:00am ETTranscriptT1790736Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1732784ccbn/T1732784norm...a negative result. We find those trials very difficult to interpret. We look at a lot of opportunities in the cancer landscape and these trials are very often disappointed when you move into Phase III and basically the Phase II trials are exploratory. These kind of trials are often very subject to bias and don't give high quality information. Our approach has been quite different in that we have a portfolio of programs. We have a critical mass in the type of people, people that we have and programs that we have and we run blinded, randomized, controlled, multicenter clinical trials where neither patient nor physician nor company knows who received the drug until the end of the trial. Those trials tend to be much more predictive of success in Phase III. You are effectively running a confirmatory Phase III study rather than an exploratory study.And that is what we did and we announced this data just over a year ago for elesclomol in stage IV metastatic melanoma. We ran a double-blind, randomized,... 2/19/2008 3:06:00 PMSynta Pharmaceuticals Corp.54.0000FinalSynta Pharmaceuticals Corp. at Roth Capital Partners 20th Annual OC Growth Stock Conference TranscriptSNTA1:00pm ETTranscriptT1732784Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1732764ccbn/T1732764normSynta Pharmaceuticals Corp. at BIO CEO & Investor Conference2/13/2008 5:06:00 PMSynta Pharmaceuticals Corp.54.0000FinalSynta Pharmaceuticals Corp. at BIO CEO & Investor Conference TranscriptSNTA11:45am ETTranscriptT1732764Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1741896ccbn/T1741896norm1/31/2008 12:05:05 AMSynta Pharmaceuticals Corp.106.0000FinalSynta Pharmaceuticals Corp. at Wachovia Healthcare Conference TranscriptSNTA3:00pm ET... - Wachovia Securities - AnalystWe are going to go ahead and get started with our next presentation, which is Synta Pharmaceuticals. As everybody knows, metastatic melanoma is the cancer of all cancers, it is the worst of the worst, and there are no treatments available. So Synta is very unique in the fact that they are the only Company that we know of that has a randomized study that shows a survival benefit in metastatic melanoma, so to talk about the Company and its merits, I will introduce their CEO, Dr. Safi Bahcall. ... TranscriptT1741896Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/srp/72268058srp/72268058norm... ##### Incorporated:DelawareWeb Site: www.syntapharma.comSIC Classification: Pharmaceutical Preparations (####) Business Description: Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with large potential markets, including cancer and chronic inflammatory diseases. Indices:Russell ####, Russell #### IPO Date: ##-##-####... 7226805887162T206SNTA2/12/2007 7:17:00 AM72268058Credit & Investment ResearchSharkRepellent.net